Shots:

• The approval is based on the P-III trial to evaluate Veklury (IV) vs PBO in a ratio (1:1) in 562 in non-hospitalized patients with COVID-19 who were at high risk for disease progression
• The results showed an 87% reduction in risk for the composite 1EPs of COVID-19 related hospitalization or all-cause death @28Day (0.7% vs 5.3%), no deaths were observed while safety profile was similar b/w Veklury & PBO across the outpatient settings
• Veklury is a nucleotide analog & is indicated for adults and pediatric patients aged ≥12yrs. for the treatment of COVID-19 requiring hospitalization in the US. The therapy is approved or authorized for temporary use in ~50 countries globally

Ref: Businesswire | Image: Gilead